Compounds for the treatment of inflammatory disorders

1. A method of treating a condition or disease selected from the group consisting of septic shock, sepsis syndrome, post ischaemic reperfusion injury, meningitis, psoriasis, an inflammatory bowel disease rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, non-insulin dependent diabetes mellitus, asthma, and chronic obstructive pulmonary disease (COPD) in a subject comprising administering to the subject in need of such treatment a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof;

wherein the compound is represented by Formula (I):

and, wherein:

X is selected from the group consisting of —S—, —C(R 4 ) 2 — or —N(R 4 )—;

T is selected from the group consisting of H (with U and V being absent), alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl, and arylalkyl, said aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl being optionally fused with one or more moieties selected from the group consisting of aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl, wherein each of any of the aforementioned alkyl, alkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl groups of T is unsubstituted or optionally independently substituted with one to four R 10 moieties;

U is selected from the group consisting of a covalent bond, —N(R 4 )—, —N(R 4 )C(R 4 ) 2 —, —N(R 4 )C(O)—, —O—, —N(R 4 )S(O) 2 —, —N(R 4 )C(O)N(R 4 )—, and —N(R 4 )C(S)N(R 4 )—;

V is absent or present, and if present V is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl, said aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl being optionally fused with one or more moieties selected from the group consisting of aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl, wherein each of any of the aforementioned alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl is unsubstituted or optionally independently substituted with one to four R 10 moieties;

Y is selected from the group consisting of a covalent bond, —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 , —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

Z is selected from the group consisting of a covalent bond. —(C(R 4 ) 2 ) n —, —N(R 4 )—, —C(O)N(R 4 )—, —N(R 4 )C(O)—, —N(R 4 )C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )—S(O) 2 —, —O—, —S—, —C(O)—, —S(O)—, and —S(O) 2 —;

n is 1 to 3;

R 1 is selected from the group consisting of H, —OR 4 , halogen, alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl, wherein each of the alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl groups of R 1 is unsubstituted or optionally independently substituted with one to four R 20 moieties, with the proviso that when Y is present and Y is N, S or O, then R 1 is not halogen;

R 2 is selected from the group consisting of H, —OR 4 , halogen, alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl, wherein each of the alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and arylalkyl groups of R 2 is unsubstituted or optionally independently substituted with one to four R 20 moieties, with the proviso that when Z is present and Z is N, S or O, then R 2 is not halogen;

each R 4 is the same or different and is independently selected from the group consisting of H, alkyl, —CH 2 C≡CCH 3 , —CH 2 C≡CCH 2 OH, and —CH 2 -cyclopropyl;

R 10 is selected from the group consisting of —OR 4 , —N(R 4 ) 2 , —O(fluoroalkyl), halogen, alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl, wherein each of the alkyl, fluoroalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylaryl and arylalkyl groups of R 10 is unsubstituted or optionally independently substituted with one to four R 30 moieties which can be the same or different, each R 30 moiety being independently selected from the group of R 30 moieties below;

R 20 is selected from the group consisting of halogen, alkyl, fluoroalkyl; and

R 30 is selected from the group consisting of halogen, alkyl, and fluoroalkyl.

2. The method of claim 1 , wherein the condition or disease is rheumatoid arthritis.

3. The method of claim 1 , wherein the condition or disease is inflammatory bowel disease.

4. The method of claim 3 , wherein the inflammatory bowel disease is Crohn's disease.

5. The method of claim 3 , wherein the inflammatory bowel disease is colitis.

6. The method of claim 1 , wherein the condition or disease is chronic obstructive pulmonary disorder.

7. The method of claim 1 , wherein the condition or disease is psoriasis.

8. The method of claim 1 , wherein the condition or disease is ankylosing spondylitis.

9. The method of claim 1 , wherein the condition or disease is psoriatic arthritis.

10. The method of claim 1 , wherein the compound is selected from the group of compounds set forth below:

Com-

pound

#

Structure

111

120

213

181

262

198

143

219

155

296

123

232

233

278

139

203

239

243